Chemotherapy for ovarian clear cell adenocarcinoma with irinotecan hydrochloride and mitomycin C

International Journal of Clinical Oncology

Volumn 1, Issue 3, 1996, Pages 157-162

  Umezawa, Satoshi ^a   Shimizu, Yoshio ^a   Takeshima, Nobuhiro ^a   Hasumi, Katsuhiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Combination chemotherapy; Irinotecan hydrochloride; Ovarian clear cell adenocarcinoma

Indexed keywords

EID: 0000977488     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02348382     Document Type: Article

References (16)

1. Coppleson M, Monaghan JM, Morrow CP, Tattersall MHN. Gynecologic Oncology: Fundamental Principles and Clinical Practice. 2nd ed. New York: Churchill Livingstone, 1992;2:878.
2. Shimizu Y, Hasumi K. Treatment of ovarian cancer at FIGO stages III and IV; prognostic factors in patients receiving neoadjuvant chemotherapy. Acta Obst Gynaec Jpn 1993;45:665-672.
3. Kaku S, HiraiY, Fujimoto I,Nakayama K, Chen J, Shimizu Y, Hamada T, Yamauchi K, Hasumi K, Masubuchi I. Clinicopathological study on clear cell carcinoma of the ovary. Acta Obst Gynaec Jpn 1989;41:875-880.
4. Monga M, Carmichael JA, Shelley WE, Kirk ME, Krepart GV, Jeffrey JF, Pater JL. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 1991;43:195-197.
5. Alexander WK, Charles VB, William RH, Kenneth DW. Ovarian clear cell adenocarcinoma. Gyncol Oncol 1989;32:342-349.
6. Shimizu Y, Umezawa S, Hasumi K. Successful treatment clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C. Jpn J Cancer Chemother 1996;23:587-593.
7. Shimizu Y, Umezawa S, Hasumi K. Evaluation of MMC-CH40 in peritoneal disease associated with ovarian clear cell adenocarcinoma by intraperitoneal administration. Oncol Gynecol 1995;11:95-98.
8. Norris HJ, Rovinowitz M. Ovarian adenocarcinoma of mesonephric type. Cancer 1971;28:1074-1081.
9. Arai K, Kitamura M, Miyashita K. Intraperitoneal repeated chemotherapy using CDDP combined with MMC for carcinomatous peritonitis. Jpn J Cancer Chemother 1993;20:1642-1644.
10. Kitamura M, Arai K, Iwasaki Y. Evaluation of CDDP-MMC by intraperitoneal administration in intraperitoneal dissemination of gastric cancer. Jpn J Cancer Chemother 1993;20:1642-1644.
11. Reshad K, Inui K, Takeuchi Y, Takahashi Y, Hitomi S. Treatment of malignant pleural effusion. Chest 1985;88:393-397.
12. Kamita H.Trend of intraperitoneal immunochemotherapies in cancerous pleuritis; effects and mechanisms. Jpn J Thora Ther 1987;46:827.
13. Takeuchi M, Dobashi K, Jujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Takitani K, Negishi T, Tamakura T, Nanizawa O, Sugawa S, Umesaki N, Maba K, AonoT, Nakano H, Noda K, Shiota M,Yakushiji M, Sugiyama T, Hashimoto M, Yajima S, Takamizawa H, Sonoda K, Takeda Y, Tomoda Y, Ohta M, Ozaki K, Hirabayashi K,Taura M, Hatae M, Nishigaki K,Taguchi T. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn Cancer Chemother 1991;18:1681-1689.
14. Nakai H, Fukushima M, Furuse K, Nakao I, Yoshimori K, Ogura T, Hara N, Sakata M, Saito H, Hasegawa K, KuriyamaT, Ogawa S, Ariyoshi H, Irie K, Kimura I, Niida H,Taguchi T. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991;18:607-612.
15. Crooke ST, Brandner WT. Mitomycin C: a review. Cancer Treat Rev 1976;3:121-127.
16. Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985;55:47-52.